Impact of semaglutide [amount hidden] on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD)

What Was Tested

Researchers studied Semaglutide in the context of atherosclerosis, cardiovascular disease & high blood pressure in this observational study publication.

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality.

Limitations inherent to retrospective claims analyses apply to this study.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

This observational cohort study utilized Komodo's Healthcare Map and included patients with ov/ob and ≥1 diagnosis of ASCVD during the baseline period with ≥12 months of insurance coverage before and after the index date.

How the Study Was Run

Semaglutide-untreated controls were randomly selected and 1:4 propensity score matched based on baseline demographics, clinical characteristics, medical costs, and HCRU.

Medical costs and HCRU were compared using generalized linear models.

What Was Measured

PubMed files the paper under topics including Glucagon-Like Peptides, United States, Atherosclerosis, Health Expenditures, Patient Acceptance of Health Care, Obesity and Propensity Score.

The authors tagged it with the keywords Atherosclerotic cardiovascular disease, I00, I10, costs, healthcare resource utilization and semaglutide.

What This Means in Plain Language

This is an observational study of Semaglutide in people with atherosclerosis, cardiovascular disease & high blood pressure.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Journal of medical economics), a journal based in England.

More context: the Semaglutide compound page, Atherosclerosis, cardiovascular disease & high blood pressure research.